CVS Health Corporation $CVS Shares Sold by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. lessened its stake in shares of CVS Health Corporation (NYSE:CVS) by 2.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 300,770 shares of the pharmacy operator’s stock after selling 8,624 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in CVS Health were worth $23,869,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in CVS. Vanguard Group Inc. raised its position in shares of CVS Health by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock valued at $9,579,508,000 after buying an additional 1,824,424 shares during the last quarter. Capital World Investors grew its stake in CVS Health by 2.1% during the third quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock worth $5,155,380,000 after buying an additional 1,419,575 shares during the period. State Street Corp boosted its position in CVS Health by 2.1% during the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after purchasing an additional 1,245,457 shares during the period. Capital International Investors boosted its position in shares of CVS Health by 3.4% in the fourth quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock worth $2,189,793,000 after buying an additional 900,153 shares during the period. Finally, Invesco Ltd. grew its position in CVS Health by 3.2% in the third quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock valued at $1,831,454,000 after acquiring an additional 760,579 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS announced a broad expansion of GLP-1 support across more than 9,000 CVS Pharmacy locations and MinuteClinic, including pharmacist guidance, lower-cost options for eligible Medicare patients, side-effect management products, and new virtual care visits. The move could strengthen CVS’s role in a fast-growing weight-loss drug market and drive more pharmacy and clinic traffic. Article: CVS Pharmacy® expands GLP‑1 support to lower costs, improve access, and help patients stay on therapy
• Positive Sentiment: Unusual options activity showed heavy call buying, suggesting traders are positioning for further upside in CVS shares. Article: A Look at CVS Health Corp (CVS) After 3.0% Gain — GF Value $77.69 vs Price $101.30
• Positive Sentiment: CVS was also highlighted in multiple articles as a momentum stock and was upgraded to Buy by Wall Street Zen, which may be reinforcing investor optimism. Article: Why CVS Health (CVS) is a Top Momentum Stock for the Long-Term
• Neutral Sentiment: CVS also published a separate newsroom item about soccer-related community events, which is likely a low-impact brand/marketing update rather than a financial driver. Article: CVS Continues To Celebrate Soccer With Community Events

Insider Activity

In related news, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the sale, the director directly owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. 0.85% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Barclays raised their price target on shares of CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 26th. TD Cowen upped their target price on CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a report on Monday, May 11th. Mizuho lifted their price objective on shares of CVS Health from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Monday, June 8th. Leerink Partners restated an “outperform” rating and issued a $98.00 target price on shares of CVS Health in a research report on Thursday, March 5th. Finally, HSBC boosted their price target on shares of CVS Health from $83.00 to $85.00 and gave the stock a “hold” rating in a research report on Tuesday, May 5th. Twenty-two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $100.68.

CVS Health Stock Up 3.4%

NYSE:CVS opened at $101.62 on Tuesday. The business’s fifty day moving average price is $89.76 and its 200 day moving average price is $81.67. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $129.66 billion, a price-to-earnings ratio of 44.77, a PEG ratio of 0.96 and a beta of 0.62. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $103.12.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm’s revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, sell-side analysts forecast that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.